Nanoparticle-based CRISPR/Cas Delivery: An Emerging Tactic for Cancer Therapy

被引:2
作者
Dilnawaz, Fahima [1 ]
Acharya, Sarbari [2 ]
机构
[1] Centurion Univ Technol & Management, Sch Engn & Technol, Dept Biotechnol, Bhubaneswar 752050, Odisha, India
[2] Deemed be Univ, Sch Appl Sci, Dept Biol, Kalinga Inst Ind Technol, Bhubaneswar 751024, Odisha, India
关键词
CRISPR; Cas9; nanotechnology; nanoparticles; cancer; gene editing; POLYMER HYBRID NANOPARTICLES; LIPID NANOPARTICLES; EDITING SYSTEM; GENE-THERAPY; CO-DELIVERY; HUMAN-CELLS; GENOME; CRISPR-CAS9; DNA; CAS9;
D O I
10.2174/0929867329666221006112615
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genome editing arose as a new promising approach for treating numerous intricate ailm ents including cancer. Over the past couple of decades, delivery technologies that have serendipitously been developed using viral vectors are successful to some extent in protein and nucleic acid delivery but their effectiveness still lags due to their efficiency, tissue targeting capabilities, and toxicity which must be further improved. With the infiltration of nanotechnology into every sphere of life, nano-vehicles can be implemented as an ideal modality that can overcome challenges, also can be introspective as new genome editing tools for cancer therapy owing to the safety and efficiency in clinical settings. Such projected substitution can help in developing highly efficacious therapy regimes which are successful in clinical settings. This emerging approach of incorporation of genome editors (CRISPR/Cas) in different nano vehicles and their utility in targeting various aspects of cancer therapy like treatment, diagnostics, modelling has been comprehensively done in this review.
引用
收藏
页码:3562 / 3581
页数:20
相关论文
共 113 条
  • [1] Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery
    Asai, Tomohiro
    Tsuzuku, Takuma
    Takahashi, Shoya
    Okamoto, Ayaka
    Dewa, Takehisa
    Nango, Mamoru
    Hyodo, Kenji
    Ishihara, Hiroshi
    Kikuchi, Hiroshi
    Oku, Naoto
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 444 (04) : 599 - 604
  • [2] CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models
    Barazesh, Mahdi
    Mohammadi, Shiva
    Bahrami, Yadollah
    Mokarram, Pooneh
    Morowvat, Mohammad Hossein
    Saidijam, Massoud
    Karimipoor, Morteza
    Kavousipour, Soudabe
    Vosoughi, Amir Reza
    Khanaki, Korosh
    [J]. CURRENT GENE THERAPY, 2021, 21 (02) : 130 - 148
  • [3] Cholesterol-Dependent Macropinocytosis and Endosomal Escape Control the Transfection Efficiency of Lipoplexes in CHO Living Cells
    Cardarelli, Francesco
    Pozzi, Daniela
    Bifone, Angelo
    Marchini, Cristina
    Caracciolo, Giulio
    [J]. MOLECULAR PHARMACEUTICS, 2012, 9 (02) : 334 - 340
  • [4] Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing
    Chang, Jin
    Chen, Xianghan
    Glass, Zachary
    Gao, Feng
    Mao, Lanqun
    Wang, Ming
    Xu, Qiaobing
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2019, 52 (03) : 665 - 675
  • [5] Controlled CRISPR-Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy
    Chen, Chao
    Ma, Yupei
    Du, Shiyu
    Wu, Yueyao
    Shen, Peiliang
    Yan, Tao
    Li, Xueqing
    Song, Yujun
    Zha, Zhengbao
    Han, Xin
    [J]. SMALL, 2021, 17 (33)
  • [6] Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics
    Chen, Fengqian
    Alphonse, Martin
    Liu, Qi
    [J]. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2020, 12 (03)
  • [7] Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles
    Chen, Zeming
    Liu, Fuyao
    Chen, Yanke
    Liu, Jun
    Wang, Xiaoying
    Chen, Ann T.
    Deng, Gang
    Zhang, Hongyi
    Liu, Jie
    Hong, Zhangyong
    Zhou, Jiangbing
    [J]. ADVANCED FUNCTIONAL MATERIALS, 2017, 27 (46)
  • [8] Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy
    Cheng, Wei-Jie
    Chen, Ling-Chun
    Ho, Hsiu-O
    Lin, Hong-Liang
    Sheu, Ming-Thau
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 7079 - 7094
  • [9] CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to enhance genome editing
    Chiang, Ting-Wei Will
    le Sage, Carlos
    Larrieu, Delphine
    Demir, Mukerrem
    Jackson, Stephen P.
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [10] Multiplex Genome Engineering Using CRISPR/Cas Systems
    Cong, Le
    Ran, F. Ann
    Cox, David
    Lin, Shuailiang
    Barretto, Robert
    Habib, Naomi
    Hsu, Patrick D.
    Wu, Xuebing
    Jiang, Wenyan
    Marraffini, Luciano A.
    Zhang, Feng
    [J]. SCIENCE, 2013, 339 (6121) : 819 - 823